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The human large intestine is populated by an extremely high density of 30 
microorganisms, collectively termed the colonic microbiota1, which plays an important 31 
role in human health and nutrition2. The survival of microbiota members from the 32 
dominant Gram-negative phylum Bacteroidetes depends on their ability to degrade 33 
dietary glycans that cannot be metabolised by the host3. The genes encoding proteins 34 
involved in the degradation of specific glycans are organised into co-regulated 35 
polysaccharide utilisation loci (PULs)4-8. The archetypal PUL has been named Sus, for 36 
starch utilisation system, and consists of 7 proteins named SusA-G8-10. Glycan 37 
degradation occurs mainly intracellularly and depends critically on the import of 38 
oligosaccharides by an outer membrane (OM) protein complex composed of an 39 
extracellular SusD-like lipoprotein and an integral membrane SusC-like TonB-40 
dependent transporter (TBDT)4-7,11-13. The presence of the partner SusD-like lipoprotein 41 
is the major difference that distinguishes SusC-like proteins from previously 42 
characterised TBDTs. Many sequenced gut Bacteroides spp encode over 100 C/D pairs, 43 
with the large majority of them having unknown functions and substrate 44 
specificities3,8,14,15. The central, unresolved question is how extracellular substrate 45 
binding by SusD proteins is coupled to OM passage via their cognate SusC transporter. 46 
Here we present X-ray crystal structures of two functionally distinct SusCD complexes 47 
purified from Bacteroides thetaiotaomicron and derive a general model for substrate 48 
translocation. The SusC transporters form homodimers, with each β-barrel protomer 49 
tightly capped by the SusD. Ligands are bound at the SusCD interface in a large 50 
solvent-excluded cavity. Molecular dynamics simulations and single channel 51 
electrophysiology reveal a "pedal bin" mechanism in which SusD moves away from 52 
SusC in a hinge-like fashion in the absence of ligand to expose the substrate binding site 53 
to the extracellular milieu. Our results provide mechanistic insights into OM nutrient 54 
import by members of the microbiota, which is of major significance for understanding 55 
the human-microbiota symbiosis.  56 
To elucidate the mechanism of substrate acquisition by SusCD complexes via X-ray 57 
crystallography we initially tried to overexpress several B. thetaiotaomicron (B. theta) SusC 58 
homologues in the OM of E. coli, but were not successful. However, we discovered that a 59 
number of SusCD complexes are expressed at high levels (~ 1 mg/l) in B. theta (Extended 60 
Data Fig. 1). The remarkable abundance of TBDTs and the paucity of OM diffusion channels 61 
such as porins in B. theta (Extended Data Fig. 1a) shows that nutrients are acquired in a 62 
fundamentally different way in Bacteroidetes compared to e.g. E. coli. A four-component 63 
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complex produced by B. theta in minimal medium could be purified to homogeneity via ion 64 
exchange chromatography (Extended Data Fig. 1b) and was identified as BT2261-2264 by 65 
mass spectrometry. The substrate of BT2261-2264 is not known, but the presence of 66 
homologues of both SusD (BT2263) and SusC (BT2264) support a function in nutrient 67 
acquisition. BT2261 and BT2262 are small OM lipoproteins (16 and 24 kDa) located on the 68 
periphery of the complex and that in B. theta are unique to the BT2261-64 system (Extended 69 
data Fig. 2). The BT2261-64 locus on the B. theta genome is not in an operon with any other 70 
genes. 71 
  72 
The structure of BT2261-64 was solved by molecular replacement using data to 2.75 Å 73 
resolution (Figs. 1a and c and Supplementary Tables 1-3) (Methods). The structure reveals 74 
that the central BT2264 (SusC) component of the complex is a typical, albeit large TBDT 75 
(984 residues), with an N-terminal plug domain inserted into a 22-stranded β-barrel (Figs. 1d 76 
and e)13. Strikingly, SusC forms homodimers burying ~2900 Å2 of surface area (Figs. 1a and 77 
c). Identical interfaces are observed for two other crystal forms (Extended Data Fig. 3), 78 
suggesting the dimer is not a crystal packing artefact. Native mass spectrometry confirms that 79 
BT2261-64 forms an octameric complex of ~400 kDa in size (Extended Data Fig. 4). To our 80 
knowledge, the dimeric organisation of SusC is unique for TBDTs. 81 
 82 
Surprisingly, the SusD-like subunit BT2263 (SusD) is located on top of the SusC forming an 83 
extracellular lid on the transporter, generating a large interface area of ~3800 Å2 (Figs. 1a and 84 
c). The SusCD interaction is stabilised by ~50 hydrogen bonds and three salt bridges, 85 
explaining the high stability of the complex in SDS-PAGE (Extended Data Fig. 1). SusC-86 
bound SusD has an identical structure compared to SusD in isolation (Fig. 2a), demonstrating 87 
that no conformational changes occur upon binding to SusC. The face of SusD that interacts 88 
with SusC is distant from the conserved four tetratricopeptide (TPR) repeats (Fig. 2a), 89 
contrasting with earlier predictions16. Instead the interaction surface includes the highly 90 
variable region that forms the substrate binding site of SusD-like proteins (Fig. 2c-e)11,16. 91 
 92 
Inspection of the SusCD interface reveals the presence of a well-defined, ~30 Å long stretch 93 
of electron density that cannot be accounted for by anything added during bacterial growth 94 
and protein purification and crystallisation. The density is modelled well by a 10-residue 95 
peptide (Fig. 3a and b and Extended Data Fig. 5). At a resolution of 2.75 Å, the peptide 96 
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sequence is ambiguous. Based on the relatively weak density for several side chains we 97 
favour the possibility that an ensemble of peptides is bound. An ensemble would explain 98 
better why we could not identify the ligand by native mass spectrometry (Extended Data Fig. 99 
4), but we cannot exclude that a unique sequence is present, or even that the density might 100 
not correspond to a peptide. To account for the sequence ambiguity, we modelled the putative 101 
peptide ligand(s) as deca-glycine (Fig. 3b). The fact that the ligand survived a large number 102 
of purification steps indicates that it is tightly bound and originates from B. theta. The ligand 103 
is present in a large cavity between SusC and SusD that is not solvent accessible (Fig. 3a). 104 
Nine out of ten residues make backbone interactions with either SusC or SusD residues (Fig. 105 
3b and Extended Data Fig. 5). A PISA17 analysis reveals that the ligand interacts more 106 
extensively with SusC compared to SusD (540 Å2 and 300 Å2 buried surface area 107 
respectively), suggesting that the complex is a transport intermediate in which a peptide 108 
ligand has been transferred from SusD to SusC and is now tightly bound as is typical for 109 
TBDT substrates13. 110 
 111 
To provide functional data for BT2261-64 we analysed expression of the complex using 112 
western blots. In contrast to known glycan uptake systems14, BT2261-64 is constitutively 113 
expressed during log phase growth in minimal medium and only upregulated on rich media 114 
during stationary phase when cell viability drops (Fig. 3c), suggesting a role for the complex 115 
during conditions of nutrient stress. These expression patterns are supported by previous 116 
transcriptomic data showing upregulation of BT2261-64 in minimal media18. A constructed 117 
ΔBT2264 (susC) knockout strain did not give a phenotype under various conditions 118 
(Methods), a result that is not surprising given that B. theta encodes over 100 SusCD systems 119 
with the majority having unknown functions3,8,14,15. We also did not observe binding to SusD 120 
(BT2263) by isothermal titration calorimetry (ITC) for two synthetic decapeptides with 121 
sequences consistent with the electron density (Methods). Despite this, the overall emerging 122 
picture is that BT2261-64 imports oligopeptides derived from other members of the 123 
microbiota. Given the extremely high microbial densities, bacterial turnover represents an 124 
underappreciated but potentially important source of nutrients in the gut. An alternative, 125 
intriguing possibility is that BT2261-64 serves as a receptor for signalling peptides, e.g in 126 
quorum sensing19. 127 
 128 
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The ligand binding site in the complex is excluded from solvent (Fig. 3a) indicating that 129 
SusD must dissociate from SusC to capture substrate from the external environment. To 130 
answer the key question as to how the substrate is delivered by SusD to the transporter we 131 
performed unbiased molecular dynamics (MD) simulations on the central hub BT2263-64 132 
(SusCD; dimer) and on BT2261-64 ("tetramer" and "octamer") in the presence and absence 133 
of a modelled peptide (holo- and apo-complex respectively; Methods). In the holo-134 
simulations, all complexes are stable during the duration of the simulations (Figs. 4a-c, 135 
Extended Data Fig. 6 and Supplementary Videos 1-3). While remaining at the SusCD 136 
interface, the conformation of the peptide varies substantially and non-uniformly in all 137 
simulations (Fig. 4a, Extended Data Fig. 7 and Supplementary Videos 1-3). The peptide 138 
movement in the simulations appears hard to reconcile with the presence of well-defined 139 
electron density in the crystal structure. The most likely explanation for this discrepancy is 140 
that the peptide sequence used in the simulations is not stable in the binding site. Together 141 
with the peptide ITC data this suggests that the BT2261-64 system is at least to some extent 142 
sequence-specific. Despite the peptide movement, the total number of hydrogen bonds with 143 
SusC and SusD remains approximately constant (Extended Data Fig. 6). 144 
 145 
Remarkably, in the majority of apo simulations SusD undergoes a hinge-like motion to 146 
expose the ligand binding site to the external environment. The extent of opening between 147 
different simulations varies due to thermal fluctuations, but in the most-open states SusD has 148 
rotated ~40-45° and has completely lost its contacts with loops L1, L3-5, and L9-L11 of 149 
SusC (Fig. 4b; Supplementary Videos 1-3). Analysed in a different way, the Cα-Cα distance 150 
between residues at the front of the complex (Thr296 in SusD and Asn203 in SusC) increases 151 
from ~6 Å in the closed, ligand-bound complexes to ~40 Å in open, ligand-free states (Fig.  152 
4c). The conformational changes are very similar in all simulations where lid opening is 153 
observed and correspond to a rigid-body movement of SusD (Extended Data Fig. 8). Loop L7 154 
of SusC moves together with SusD and is responsible for the majority of the remaining 155 
SusCD interactions in the open state. We have named L7 the hinge loop, and it is the region 156 
in SusC that exhibits the largest conformational differences between the holo- and apo-157 
simulations (Extended Data Fig. 8). The hinge point at the base of L7 is located at the back of 158 
the complex, near the SusD lipid anchor (Fig. 4b). The octamer simulation demonstrates that 159 
SusC dimerisation does not impede opening of the SusD lid and moreover suggests that both 160 
SusCD hubs function independently (Fig. 4c, Extended Data Fig. 9 and Supplementary Video 161 
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3). A final implication of the computational results is that since removal of the ligand 162 
produces a mechanistically sensible response (i.e. SusD lid opening), the MD simulations 163 
support our modelling of the BT2261-64 ligand as an oligopeptide. Even if the ligand is not a 164 
peptide, its location at the CD interface would stabilise the closed state of the complex, i.e. 165 
the results of the MD simulations of the holo complex would most likely not depend on the 166 
assigned identity of the ligand. This notion is supported by the fact that the SusD lid remains 167 
closed, despite the fact that the peptide assumes many different conformations during the 168 
simulations. 169 
 170 
The large number and sequence diversity of SusCD gene pairs in Bacteroidetes and 171 
especially Bacteroides spp3,8,14,15 leads to the important question whether the BT2261-64 172 
structure and transport mechanism are representative for those of other SusCD complexes. To 173 
address this issue we determined the crystal structure of BT1762-1763, which is part of a 7-174 
gene PUL with an established function in levan (β2,6-fructan) degradation4. No other 175 
proteins co-purify with BT1762-63 (Extended Data Fig. 1d), suggesting that the accessory 176 
PUL OM lipoproteins are not an integral part of this complex. Native mass spectrometry and 177 
SEC-MALS show that BT1763 (SusC) also forms homodimers (Extended Data Fig. 4). The 178 
crystal structures confirm this, and show that the relative orientations of BT1762 (SusD) and 179 
BT1763 are the same as in the BT2263-64 complex, with SusD capping SusC (Figs. 1b and 180 
2b). As is the case for BT2263-64, binding to SusC does not cause significant conformational 181 
changes in the SusD (Fig. 2b). Importantly, the hinge loop (L7) observed in BT2264 is also 182 
present in BT1763 (Fig. 1f). No substrate is bound in the BT1762-63 structure, in accordance 183 
with the known high specificity of the complex4 and the fact that no substrate was added 184 
during cell growth. The reason that the SusD lid is closed is likely related to the fact that 185 
crystallisation favours stable, compact states. Unexpectedly, no density is observed for the 186 
plug domain of BT1763 (Fig. 1f), and SDS-PAGE confirms the ~20 kDa lower molecular 187 
weight of BT1763 from crystal-containing drops (Fig. 4e). Removal of the plug and the 188 
preceding DUF4480 domain also occurs after prolonged incubation of freshly isolated 189 
complex, presumably via proteolytic cleavage by a co-purified contaminant (Fig. 4e). We 190 
took advantage of these different BT1762-63 complexes to obtain experimental evidence for 191 
opening of the SusD lid by single channel electrophysiology. Reconstitution of freshly 192 
purified, full-length SusCD complex in the planar lipid bilayer generates very small and 193 
relatively stable ion currents, consistent with the absence of a large channel in intact TBDTs. 194 
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By contrast, plug-less complex (SusCD -plug) produces large channels with average 195 
conductance values of ~1.5 nS. The traces are extremely noisy and a wide range of 196 
conductance values are observed including zero, indicating dynamic opening and closing 197 
events (Fig. 4d). To exclude the possibility that gating by extracellular SusC loops was 198 
responsible for the observed dynamics in the plug-less BT1762-63 complex we isolated 199 
truncated BT1763 from SDS-PAGE gels, followed by refolding and reconstitution (SusC -200 
plug). This produces large channels with similar conductance values (~3 nS) as measured for 201 
a genetically created plug-less TBDT, FhuA20. In contrast to those of plug-less SusCD, the 202 
plug-less SusC channels are stable, indicating that the extracellular loops of SusC are not 203 
responsible for the dynamics observed in plug-less SusCD (Fig. 4d). Lastly, full-length SusC 204 
(SusC + plug) behaves similarly to SusCD + plug and does not form channels, demonstrating 205 
that refolding and reconstitution generates correctly folded transporters. The 206 
electrophysiology data for the levan importer therefore provide experimental evidence that 207 
fully supports the dynamic opening and closing of the SusD lid in ligand-free complexes 208 
observed by MD simulations of the putative peptide importer. 209 
 210 
To provide functional support for the structures and transport mechanism we focused on 211 
BT1762-63 because robust growth of B. theta on levan is dependent on an intact copy of 212 
BT1762 (ref. 4). We predicted the aromatic residues Trp85, Trp286, Tyr395 and Trp396 as 213 
well as the disulphide-bonded residues Cys298 and Cys299 to be in or close to the putative 214 
levan binding site on BT1762 (SusD) based on sequence alignment and comparison with the 215 
ligand-bound structures of the archetypal SusD (BT3071; Fig. 2) and BT1043 (PDB 216 
3EHN)21. Individual alanine mutants were produced in E. coli and levan binding to purified 217 
BT1762 variants was assessed by ITC. Mutation of Trp85 and Cys298 resulted in complete 218 
loss of levan binding, while the Tyr395 mutant displayed ~6-fold loss of affinity (Extended 219 
Data Fig. 10). Mutation of other aromatic residues, including ones far away from the binding 220 
site had no effect (e.g. Tyr280, Trp479). The locations of the residues abolishing levan 221 
binding to SusD are in excellent agreement with the positioning of SusD within the SusCD 222 
complex and also with the location of the ligand binding site in BT2261-64 (Fig. 3d). 223 
 224 
Combining our structural and functional data and previous mechanistic insights for TBDTs13 225 
we propose a "pedal bin" mechanism for nutrient acquisition by SusCD-like systems (Fig. 226 
4f). (i) In the absence of substrate, the SusD lid of the empty transporter is mobile and 227 
samples a range of conformational states. (ii) Upon substrate binding, the closed state 228 
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represented by the crystal structures is stabilised by ligand interactions with both SusC and 229 
SusD (Fig. 3b). (iii) The final step in transport involves TonB binding to the TonB box of the 230 
transporter22,23 to generate conformational changes in the plug and possibly extracellular 231 
loops of SusC that lead to substrate release and the formation of a transport channel into the 232 
periplasmic space13. The TonB box of BT2264 (residues 23-29) is not visible in the 233 
structures, consistent with the view that this segment is mobile and accessible in ligand-234 
bound TBDTs to allow binding/recognition by TonB13. Residue L120 of the plug loop in 235 
BT2264 contacts the peptide via van der Waals interactions (Fig. 3b), providing a direct link 236 
between the ligand and the SusC plug and a potential way to signal TonB that the binding site 237 
in BT2264 is occupied13. The TonB-induced substrate dissociation reverts the transporter 238 
back to the dynamic open state, and the energy input from the ExbBD-TonB24,25 system is 239 
therefore equivalent to pressing the pedal to open the SusCD bin (Fig. 4e). The proposed 240 
transport mechanism also provides a rationale for the essential requirement of a surface 241 
located endo-acting enzyme in many PULs4-6,10since formation of the closed ‘transport 242 
competent’ complex appears to involve envelopment of the whole ligand molecule (Fig. 3a), 243 
precluding import of undigested, high molecular weight glycans. 244 
 245 
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FIGURE LEGENDS 333 
Figure 1 | Overall architecture of SusCD complexes. a, b, Cartoon views from the side for 334 
BT2261-64 (a) and BT1762-63 (b) rotated by 90º, with individual subunits labelled. OM, 335 
outer membrane. c, Surface representation of BT2261-64 from the outside of the cell. d, e, 336 
Architecture of BT2264 (SusC-like) viewed from the extracellular side (d) and from the 337 
plane of the membrane (e) with several extracellular loops indicated (L). The plug domain in 338 
the 22-stranded β-barrel is dark blue, and the N-terminal ten residues of BT2263 (SusD-like) 339 
including the lipid anchor are shown as stick models in magenta. Loop L7 is shown in 340 
orange. f, View of the BT1762-63 dimer from the periplasmic side. The L7 loops (orange) of 341 
BT1763 (SusC-like) and the functionally important residue Trp85 in BT1762 (SusD-like) are 342 
shown as space-filling models. 343 
 344 
Figure 2 | The SusCD interaction involves the ligand binding face of SusD. a Cartoon 345 
overlay of BT2263 SusD in isolation (rainbow colouring; N-terminus blue) and within the 346 
BT2261-2264 complex (magenta). The four TPR domains are labelled and BT2264 SusC is 347 
shown as a transparent surface. b, Cartoon overlay for BT1762 in isolation (rainbow 348 
colouring) and within BT1762-1763 (red). BT1763 SusC is shown in green. c, Superposition 349 
of BT2263 with the archetypal SusD BT3701 in grey (PDB ID: 3CKB), viewed from the 350 
bottom (top panel) and from the side as in a. Bound maltotriose in BT3701 is shown as a 351 
space-filling model (carbons, black; oxygens, red). d, BT2263 with residues forming 352 
hydrogen bonds and salt bridges with BT2264 coloured yellow. e, Superposition as in c, with 353 
the putative peptide ligand of BT2261-2264 included to show binding site overlap. 354 
 355 
Figure 3 | The SusCD ligand binding site is conserved. a, Side views of BT2261-64 356 
showing the putative peptide ligand in green. b, Close-up of the binding site, showing SusC 357 
(yellow) and SusD (magenta) residues forming hydrogen bonds with the peptide backbone. 358 
Loop L7 is orange and the plug loop dark blue. 2Fo-Fc density for deca-glycine is shown as a 359 
blue mesh at 1.5σ. c, Western blot analysis of BT2261-64 expression via FLAG-tagged 360 
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BT2263 in rich medium (TYG) and fructose minimal medium (MM-Frc) (representative of 361 
three independent experiments). Bottom panel shows corresponding colony forming unit 362 
(cfu) values (n =3, average +/- standard deviation). d, Mutational analysis of levan binding 363 
by BT1762 (red). Views are from the periplasmic side (left panel) and from the front. 364 
Residues that abolish levan binding are shown in yellow with those that do not affect levan 365 
binding in cyan. BT2263 (magenta) with bound deca-glycine (green) is superposed to show 366 
the conservation of the binding sites. 367 
 368 
Figure 4 | SusCD complexes transport their substrates via a pedal bin mechanism. a and 369 
b, MD simulation snapshots of holo (a) and apo (b) BT2263-64 after 0 ns and 500 ns. SusC 370 
is coloured yellow with the plug domain in dark blue; SusD is shown in magenta. Cα atoms 371 
of Asn203 in SusC and Thr296 in SusD are shown as black spheres. c, Average distances vs. 372 
simulation time between SusC-Asn203 and SusD-Thr296 for SusCD dimers (green), 373 
BT2261-64 tetramers (red), and the (BT2261-64)x2 octamer (blue). d, Single channel 374 
electrophysiology traces and corresponding all-point histograms for BT1762-63 complexes 375 
(SusCD +/- plug) and for BT1763 (SusC +/- plug). Traces and histograms are representatives 376 
of 10 experiments. e, SDS-PAGE of BT1762-63 before (lane 1) and after (lane 2) incubation 377 
for 2 weeks at room temperature, and from crystal drops (lane 3). f, General mechanism for 378 
nutrient uptake via SusCD transport complexes, colour-coded as in panels a and b. Ligand is 379 
shown as a green wavy line and the C-terminal domain of TonB that interacts with the SusC 380 
plug is cyan. 381 
 382 
METHODS 383 
Growth of B. theta, OM isolation and purification of SusCD complexes. Native BT2261-384 
2264 complex. Wild-type B. theta was grown on minimal media containing fructose (0.5% 385 
w/v) as a carbon source at 37°C under anaerobic conditions overnight. At A600 of 1.5-2.0, 386 
cells were harvested by centrifugation at 11,305 x g for 30 minutes. Cells were resuspended 387 
in TSB buffer (20 mM Tris, 300 mM NaCl pH 8) and lysed at a pressure of 23 kpsi using a 388 
cell disrupter (Constant Systems 0.75 kW). The cells were centrifuged at 205,000 x g for 1 389 
hour to collect total membranes. The pellets were resuspended and homogenised in 20 mM 390 
HEPES pH 7.5 containing 0.5 % (w/v) sodium lauroyl sarcosine. Typically, 100 ml buffer 391 
was used for 2 l of cells. The sample was incubated while stirring at 20 °C for 30 minutes and 392 
centrifuged at 205,000 x g for 30 minutes. The supernatant was discarded and the process 393 
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was repeated. The clear, translucent pellets containing the OM proteins were resuspended and 394 
homogenised in 1.5 % (w/v) lauryldimethylamine-N-oxide (LDAO) buffer (10 mM Hepes, 395 
50 mM NaCl pH 7.5) and incubated while stirring at 4°C overnight. The sample was 396 
centrifuged at 205,000 x g for 45 minutes and the supernatant containing OM proteins was 397 
collected. The sample was passed through a 0.45 µm filter, loaded on a 6 ml Resource Q 398 
anion exchange column and eluted with a linear gradient of NaCl (Extended Data Fig. 1). The 399 
BT2261-2264 peak was collected and further purified by gel filtration chromatography in 10 400 
mM Hepes, 100 mM NaCl, 0.12% n-decyl-β-D-maltoside (DM) pH 7.5 using a HiLoad 401 
16/60 Superdex 200 column. Peak fractions were pooled and the buffer was exchanged to 10 402 
mM Hepes, 100 mM NaCl, 0.4% Tetraethylene Glycol Monooctyl Ether (C8E4) pH 7.5 using 403 
a 100 kD MWCO ultrafiltration device (Millipore). The protein was concentrated to 7-10 404 
mg/ml, aliquoted and flash-frozen in liquid nitrogen. 405 
 Selenomethionine-substituted BT2261-2264 complex. 10 litres of wild type B. theta 406 
were grown in rich TYG-haematin media at 37°C anaerobically for 20 hours to A600 of 1.2, 407 
and harvested by centrifugation at 11,305 x g for 30 minutes. The cells were resuspended and 408 
used to inoculate 10 litres of minimal media containing 0.5 % (w/v) fructose to induce 409 
expression of BT2261-2264. Seleno-methionine (SeMet) enrichment was performed based on 410 
the well-established methionine biosynthesis inhibition protocol for E. coli 26. Cells were 411 
incubated at 37°C anaerobically for 30 minutes before the addition of amino acids (Lys, Phe, 412 
Thr, Leu, Ile, Val) and SeMet (60 mg/l). The cells were incubated for a further 17 hours to a 413 
final A600 of ~1.7 and harvested. Bacteria were processed and BT2261-64 was purified as 414 
described above.  415 
BT1762-1763 complex. A 4xAla linker and 6xHis-tag were added to the C-terminus of 416 
genomic BT1762 (susD) using pExchange-tdk11. The mutated B. theta cells were grown on 417 
minimal media with 0.5% fructose under anaerobic conditions as fructose is known to 418 
activate expression of the levan PUL (BT1757-1763) (ref. 4). Cells were harvested and 419 
processed as outlined above. Following solubilisation with LDAO, the His-tagged complex 420 
was purified by cobalt-affinity chromatography (Talon) followed by gel filtration with a 421 
HiLoad 16/60 Superdex 200 column in 10 mM Hepes, 100 mM NaCl, 0.12% DM pH 7.5. 422 
For crystallisation the detergent was exchanged to C8E4 via a second gel filtration step in 10 423 
mM Hepes, 100 mM NaCl, 0.4% C8E4 pH 7.5. 424 
Overexpression and purification of BT2262 and BT2263. The mature parts of BT2262 and 425 
BT2263 lacking the N-terminal cysteine were amplified using PCR for ligation independent 426 
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cloning into a pET9 vector containing a kanamycin resistance gene for selection, a PelB 427 
signal sequence for targeting proteins to the periplasm and a C-terminal TEV protease-428 
cleavable 10xHis-tag. After TEV cleavage, the sequence "SM" is added to the first residue of 429 
the cloned sequence. The vector was digested using BsaI and annealed with the insert using 430 
T4 DNA polymerase. Proteins were expressed in BL21 (DE3) E. coli cells grown in LB 431 
media at 37°C to A600 of ~0.6 and induced with 0.2 mM IPTG then incubated at 18 °C 432 
overnight. Cells were harvested at 2,826 x g for 30 minutes, resuspended in TSB buffer and 433 
lysed at 23 kpsi using a cell disrupter. The lysed cells were centrifuged at 205,000 x g for 45 434 
minutes and the supernatant was collected. The proteins were purified using nickel affinity 435 
chromatography (Chelating Sepharose; GE Healthcare) and eluted with TSB buffer 436 
containing 250 mM imidazole. The buffer was exchanged to TEV cleavage buffer (50 mM 437 
Tris, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM TCEP pH 8). TEV protease was added to a ~ 5-438 
10:1 w/w ratio (protein:TEV) and the His-tag was cleaved overnight at room temperature 439 
with gentle rocking. The cleaved proteins were subjected to a second round of nickel affinity 440 
chromatography. Tag-less proteins were further purified by gel filtration in 10 mM Hepes, 441 
100 mM NaCl pH 7.5 using a HiLoad 16/60 Superdex 200 column, and concentrated to ~10-442 
15 mg/ml for crystallisation. 443 
Crystallisation of BT2262 and BT2263. Sitting drop crystallisation trials were set up using 444 
a Mosquito crystallisation robot (TTP Labtech) using commercial screens (Molecular 445 
Dimensions Structure, Index, PACT and JCSG+ screens). Initial hits were obtained in 446 
Structure, #37 for BT2263 (0.2 M sodium acetate trihydrate, 0.1 M Tris pH 8.5, 30% w/v 447 
PEG4000) and Structure, #30 for BT2262 (2 M ammonium sulfate, 0.1 M Hepes pH 7.5, 2% 448 
w/v PEG400). 449 
Crystallisation and structure determination of BT1762. The mature part of BT1762 was 450 
overexpressed in the cytoplasmic space of E. coli BL21(DE3) and purified by cobalt affinity 451 
chromatography. The protein was crystalized using the sitting drop method using a Mosquito 452 
robot (TTP Labtech). Rod-like crystals grew in 2.0 M ammonium sulfate, 100 mM sodium 453 
acetate pH 4.6 and 8% PEG 4000. Both native and SeMet data were collected on beamline 454 
I03 at Diamond light source (Didcot, UK). Data were processed and integrated to 1.8 Å with 455 
XDS27 and scaled with Aimless28,29. Space group determination was tested with Pointless29. 456 
The phase problem was solved by SeMet single-wavelength anomalous dispersion (SAD) 457 
using HKL2MAP30 and Shelx C/D/E pipeline31. An initial model was produced by 458 
Buccaneer32 using the SAD data and used as a search model for molecular replacement using 459 
Molrep33 on the native data. The model was completed using iterative cycles of refinement 460 
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with Refmac5 (ref. 34) and manual model-building using COOT35. The Rfree set of reflections 461 
was 5% of the unique reflections, randomly selected. The model was validated using 462 
Molprobity36.  463 
Crystallisation and structure determination of OM complexes. BT2261-2264. Sitting drop 464 
crystallisation trials were set up using a Mosquito crystallisation robot (TTP Labtech) using 465 
commercial screens (Molecular Dimensions MemGold 1 and 2) and in-house screens. The 466 
triclinic and orthorhombic crystals for native BT2261-64 as well as the crystals for SeMet-467 
substituted complex were produced by the same condition (MemGold 2 #44; 0.2 M 468 
magnesium formate dihydrate, 0.05 M Tris pH 8, 18-22 % w/v PEG 3350), although the 469 
triclinic crystals occurred very infrequently. Diffraction data were collected at 100 K at the 470 
Diamond Light Source (Didcot, UK), on beamlines I03 (BT2263), I04 (BT2261-2264 and 471 
BT1762-1763) and I24 (BT2261-2264). All diffraction data were processed with XDS and 472 
Pointless was used for space group determination. Data were scaled using Aimless. 473 
 After obtaining well-diffracting crystals for native BT2261-64 we performed 474 
molecular replacement (MR) trials in Phaser37 with both crystal forms, using components 475 
available within the PDB at that time. These consisted of FepA38 (PDB ID 1FEP; 14% 476 
identity to BT2264), BT2259 (PDB ID 4Q69; 26% identity to BT2263) and BT2261 (PDB 477 
ID 3H3I). However, none of these trials produced a plausible solution, including searches 478 
that were performed with Sculptor-modified39 search models. We then obtained crystals of 479 
soluble BT2263 and solved its structure via MR using BT2259 as a search model (26% 480 
sequence identity). Subsequently a definite MR solution for the complex was found by 481 
Phaser for a P1 crystal using BT2263 and Sculptor-modified FepA as search models 482 
(RFZ=14.7 TFZ=* PAK=0 LLG=503 RFZ=10.4 TFZ=29.9 PAK=0 LLG=1195 RFZ=5.5 483 
TFZ=10.3 PAK=3 LLG=1263 RFZ=5.7 TFZ=9.0 PAK=7 LLG=1220 LLG=1789; 2 copies 484 
each of BT2263 and BT2264). Subsequent Autobuilding within Phenix39 yielded a model 485 
with Rfree of ~44%. Placement of two copies of BT2261 via MR was straightforward at this 486 
stage. Subsequent rounds of manual building of BT2264 and the N-terminal domain of 487 
BT2262 within COOT35 depended critically on using density-modified maps produced by 488 
RESOLVE40, in particular after application of 2-fold non-crystallographic symmetry (NCS). 489 
During the later stages of model building and Phenix refinement, we solved the structure of 490 
BT2262 by molecular replacement using the N-terminal domain (residues 4-110) from the 491 
complex as a search model. When the Rfree of the model for the complex reached ~28%, 492 
BT2262 was placed in the density, guided by its N-terminal domain. Refinement of B-factors 493 
was done isotropically including TLS, with each protein chain taken as a separate group. 494 
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NCS was not used. For all structures, protein geometry was validated with MolProbity36. 495 
Figures were produced with PyMOL41 (Schrödinger LLC). In the final model of BT2261-64, 496 
only one copy of BT2262 is visible within the complex (residues 4-212; numbering from the 497 
first residue of the mature sequences), with poor density for the C-terminal domain. Besides 498 
BT2262, the final model contains two copies of BT2264 (residues 37-984), two copies of 499 
BT2263 (residues 1-480) and two copies of BT2261 (residues 3-148). Of the two complexes 500 
in the asymmetric unit, the best density is observed for the complex consisting of chains 501 
ABFG, and the electron density maps for the peptide reported here were based on this 502 
complex. For the other complex in the P1 asymmetric unit (chains CDE) as well as for some 503 
of the complexes in the other space groups, the peptide density is slightly different. It is not 504 
clear at this point whether the differences in density for the peptide are a consequence of the 505 
possible presence of a bound ensemble. 506 
 During the later stages of structure refinement of BT2261-64 we also obtained 507 
diffracting crystals for SeMet-substituted complex in space group P21. Both SAD and MAD 508 
datasets were collected for these crystals but none of these provided phases of sufficient 509 
quality to solve the structure de novo. Given that the anomalous signal was weak, the failure 510 
of phasing was most likely due to a low level of SeMet incorporation by B. theta. However, 511 
anomalous difference maps could be produced that provided a useful independent registry 512 
check via the 51 methionine residues present in the tetrameric BT2261-64 complex. 513 
 The structures of the BT2261-2264 complex in space groups P212121 and P21 were 514 
solved by MR in Phaser using the individual components from the P1 crystals as search 515 
models, and refined with Phenix. The orthorhombic complex contains 2 molecules of each of 516 
the subunits, with the C-terminal domains of both BT2262 subunits missing. In the 517 
monoclinic, SeMet complex, no density is visible for either of the BT2262 subunits, 518 
confirming the dynamic nature of this subunit (Extended Data Fig. 3). Extended Data Fig. 3 519 
also shows that the triclinic structure has the lowest B-factors and consequently yielded the 520 
best-quality maps. The data collection and refinement statistics are summarised in 521 
Supplementary Table 1 (BT2261-64) and 2 (BT2263, BT2262 and BT1762).  522 
 BT1762-1763. Two different crystal forms were obtained for BT1762-63. First, a 523 
single diamond-shaped plate was obtained from MemGold 2, condition 18 (crystal form 1; 524 
0.1 M magnesium formate dihydrate, 0.1 M MOPS pH 7, 17 % w/v PEG 3350), and 525 
cryoprotected by the addition of ~20% glycerol. A dataset to 3.1 Å resolution collected on 526 
this crystal at DLS beamline I04 generated a definite MR solution with Phaser (RFZ=6.8 527 
TFZ=14.4 PAK=0 LLG=173 TFZ==14.7 RFZ=7.0 TFZ=7.6 PAK=9 LLG=627 TFZ==10.4 528 
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LLG=807 TFZ==10.0; space group P21212), using the BT1762 structure and a Sculptor-529 
generated model of BT2264 (21% sequence identity) as search models. In this crystal, there 530 
is only one SusC protomer within the asymmetric unit, with the SusC homodimer generated 531 
by crystallographic symmetry. Autobuilding within Phenix resulted in a model with Rfree 532 
~43-44% (R ~39%), comparable to BT2261-64 at a similar stage of refinement. Due to the 533 
lack of non-crystallographic symmetry (NCS) the maps were of insufficient quality to build a 534 
more complete model for BT1763. We then obtained another crystal form (crystal form 2; 535 
P212121) from a different preparation with 2 molecules in the AU from 18-20% w/v PEG 536 
3350, 50 mM Hepes pH 7.0, 0.2 M NH4NO3. The best crystal diffracted X-rays to ~3.0 Å 537 
resolution. Running Phaser with BT1762 and the partial, Autobuilt model of BT1763 gave a 538 
single, definite solution (RFZ=11.7 TFZ=24.0 PAK=0 LLG=610 TFZ==27.7 RF++ 539 
TFZ=45.1 PAK=0 LLG=1771 TFZ==42.7 RFZ=6.1 TFZ=36.4 PAK=0 LLG=2747 540 
TFZ==37.0 (& TFZ==31.6) LLG+=(2747 & 3697) LLG=3740 TFZ==38.1 PAK=0 541 
LLG=3740 TFZ==41.5). Following Autobuilding within Phenix, a model was built via 542 
iterative cycles of manual building and refinement within Phenix. During later stages of 543 
refinement, NCS was omitted and TLS refinement of B-factors was applied (one domain per 544 
chain). The structure of crystal form 1 was then solved via MR, followed by refinement in 545 
Phenix as described above. The data collection and refinement statistics for BT1762-63 are 546 
summarised in Supplementary Table 3. 547 
Knockout construction of BT2264 and growth experiments. Two rounds of PCR were 548 
used to create a product with the desired sequence, including 1000 bp upstream and 549 
downstream of the knockout region. This was ligated with pExchange-tdk vector11 which was 550 
then used for genetic recombination. The BT2264 knockout and WT strains were grown on 551 
TYG rich media and minimal media containing 0.5% fructose or glucose. In addition, growth 552 
on MM-Fructose plus tryptone (1%) was tested. The cells were incubated for 72 hours at 37 553 
°C under anaerobic conditions and the A600 was taken every 15 minutes using a plate reader. 554 
The BT2264 knockout strain showed no growth phenotype under any of the conditions 555 
tested.  556 
Western blot analysis. pExchange-tdk11 was used to add a 4xAla linker and FLAG-tag 557 
(DYDDDDK) to the C-terminus of BT2263 (SusD) in WT B. theta. The resulting mutant 558 
strain was grown in TYG rich media and minimal media containing 0.5% fructose, and 559 
samples were collected over 24 hrs. The whole cells were diluted to relative CFU (colony 560 
forming units) using Bugbuster detergent and solubilised. The solubilised material was 561 
analysed by western blot using Sigma F7425 Anti-FLAG (1 in 2000 dilution) as the primary 562 
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antibody and Goat anti-rabbit IgG-HRP: sc-2004, Santa Cruz Biotechnology (1 in 5000 563 
dilution) as the secondary antibody.  564 
Isothermal Titration Calorimetry. BT1762. Site directed mutagenesis of the mature form of 565 
BT1762 cloned into pRSETA (Invitrogen) was performed using the Quikchange kit (Agilent) 566 
according to the manufacturers protocol. The affinity of wild type and mutants (numbered 567 
from the mature form of the protein) for levan was quantified by isothermal titration 568 
calorimetry (ITC) using a Microcal VP-ITC. Briefly, the protein sample (50–60 μM), stirred 569 
at 300 rpm in a 1.4 ml reaction cell, was injected with 27-29 x 10 μl aliquots of levan (0.5-2% 570 
w/v; Montana polysaccharides, USA). Titrations were carried out in 20mM Na-HEPES 571 
buffer, pH 7.5 at 25 °C. Integrated binding heats, minus dilution heat controls, were fit to a 572 
single set of sites binding model to derive Ka using Microcal Origin v7.0. At least two 573 
independent titrations were performed for each protein tested. The molar concentration of 574 
binding sites present in levan was determined by altering the concentration of ligand used for 575 
regression of the isotherm until the fit yielded a value of 1 for n (number of binding sites on 576 
each molecule of protein) for the wild-type and using this value for all titrations. The 577 
assumption that n = 1 was deemed valid based on the structure and mutant binding data.  578 
 BT2263. We probed the possible interaction between two synthetic oligopeptides 579 
(Biomatik Corporation, USA) and BT2263 SusD-like. The first peptide was a hypothetical, 580 
negatively charged sequence consistent with the density (GSSGGQQEGG), whereas the 581 
second contained several positively charged residues (GDSGSKQKKG), again based on a 582 
possible assignment. In addition, the binding to poly-DL-alanine (Sigma P9003; Mw 1000-583 
5000) was investigated. Peptides at 10 mM in buffer were titrated to 40 μM BT2263 as 584 
described above.  585 
Native mass spectrometry. The protein sample was buffer exchanged to 1 M ammonium 586 
acetate containing 0.5% C8E4 utilizing a biospin 6 column (Bio-Rad). Typically, 2-3 µl of the 587 
protein samples were loaded onto a gold-coated borosilicate capillary (1 mm outer diameter). 588 
Proteins were transmitted into a Synapt HDMS mass spectrometer (Waters) modified to 589 
facilitate the transmission of high mass species via a nano-ESI apparatus. Instrument 590 
parameters were set as follows: backing pressure- 6 mBar, capillary voltage- 1.6 kV, cone 591 
voltage- 170 V, trap and transfer collision energy were 200 V for the BT2261-2264 complex 592 
and 100 V for BT1762-1763. Data analysis was carried out using Masslynx 4.1 (Waters). 593 
Size exclusion chromatography multi-angle light scattering (SEC-MALS). SEC-MALS 594 
was performed using an ÄKTA Pure with Superdex 200 10/300 GL Increase (GE 595 
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Healthcare), with in-line DAWN HELIOS II MALS detector (eight fixed angles) and Optilab 596 
T-rEX differential refractometer (Wyatt Technology). BT1762-63 (100 µl of 7 mg/ml) was 597 
analysed in 10 mM Hepes pH 7.5, 150 mM NaCl, 0.05% dodecyl-β-D-maltoside. Data were 598 
collected and analysed using ASTRA 6 (Wyatt Technology). Molecular weights for the 599 
protein-detergent complex and its protein and detergent constituents were determined through 600 
protein-conjugate analysis with Zimm plot extrapolation using dn/dc values of 0.1850 ml/g 601 
and 0.1435 ml/g for protein and detergent respectively, and a protein UV extinction 602 
coefficient of 1.86 ml/mg/cm. 603 
Refolding of Sus proteins from SDS-PAGE. The proteins were refolded from gels using a 604 
simple refolding protocol. Briefly, the samples were mixed with loading buffer (final 605 
concentrations: 75 mM Tris pH 6.8, 15 % glycerol, 0.6 % SDS, 5 % β-Mercaptoethanol, 0.01 606 
mg/ml bromophenol blue) and heated for 15 min at 90° C. Each sample was loaded onto 607 
multiple wells for a higher yield on a 12% SDS gel along with the PageRulerTM Prestained 608 
Protein ladder (Thermo Scientific, Product no. 26617). Part of the gel was silver stained. Thin 609 
slices of the unstained gel were excised along the expected size of the band by comparing 610 
with its stained counterpart and were transferred to a vial containing 1% Genapol. Gel pieces 611 
were crushed gently for about half an hour using a micro pestle to make the solution 612 
homogenous. The suspension was kept for overnight incubation at 8°C with 550 rpm shaking 613 
on a Thermomixer. Following overnight incubation, the mixture was centrifuged at 3500 x g 614 
for 30 min and the supernatant was collected and checked for channel activity by 615 
electrophysiology. 616 
Single Channel Electrophysiology. Electrophysiology measurements were carried out using 617 
a single channel reconstitution protocol as described elsewhere42. In short, a teflon cuvette 618 
was used in which a 25 μm thick Teflon film with an aperture size of around 50 -100 μm was 619 
inserted between the two chambers.  1-2 μl of a solution containing 1 % Hexadecane in 620 
Hexane was used to impregnate the area around the aperture to make it more hydrophobic 621 
(lipophilic) and left to dry. The two chambers were filled with 1 M KCl and 10 mM HEPES 622 
pH 7.  Around 2 μl solution of 5 mg DPhPC (diphytanoylphosphatidylcholine, Avanti polar 623 
lipids, Alabaster, AL) dissolved in 1 ml n-pentane was used to form the membrane using the 624 
Montal and Muller technique43. A pair of Ag/AgCl electrodes (World Precision Instruments, 625 
Sarasota, FL) was used to measure the ionic current across the membrane where one of the 626 
electrodes is connected to the cis (ground) side of the membrane and the other was connected 627 
to the trans headstage of the Axopatch 200B amplifier (Axon Instruments).  Protein dissolved 628 
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in 1 % Genapol was always added to the cis side of the membrane.  The ion current trace was 629 
filtered using a low pass Bessel filter at 10 kHz and was recorded using a sampling frequency 630 
of 50 kHz. Data were analysed using the Clampfit program. The data thus obtained were 631 
filtered at 5 kHz for obtaining a clear view of the traces. The data shown in Fig. 4d were 632 
obtained at +50 mV. 633 
Molecular Dynamics simulations. Molecular dynamics (MD) simulations were carried out 634 
with GROMACS 4.6.5 (ref. 44) using the all atom CHARMM36 force field for protein, lipids 635 
and ions45,46 using standard procedures for membrane proteins47. Long-range Coulomb 636 
interactions were calculated using the partice-mesh Ewald (PME) summation method with a 637 
short-range cutoff of 1.2 nm and a Fourier grid spacing of 0.12 nm. At the same time, 638 
Lennard-Jones interactions were considered up to a distance of 1 nm, and a switch function 639 
was used to smoothly switch off the interactions to reach zero at 1.2 nm. The unbiased 640 
simulations were performed under constant pressure (1 bar) and constant temperature (300 K) 641 
with a time step of 2 fs by applying constraints to the bonds of hydrogen atoms using the 642 
LINCS algorithm48. The MD simulations were performed for different starting structures 643 
(dimer, tetramer and octamer) of the BT2261-2264 SusCD complex. The missing residues in 644 
the periplasmic turn (L570-F578) of SusC were modeled using Modeler 9.12 (ref. 49). In 645 
case of the octamer, the missing second copy of BT2261 was added manually. The starting 646 
structures of the SusCD complex in the peptide-bound conformations were embedded in a 647 
symmetric bilayer consisting of POPE (palmitoyloleoyl-phosphatidylethanolamine) lipids 648 
using the membrane builder in the CHARMM-GUI50. Subsequently, the lipid bilayer and the 649 
protein were solvated using a TIP3P water box and further neutralized by adding the 650 
appropriate number of potassium ions. The holo systems were equilibrated using the well-651 
established protocol developed in the CHARMM-GUI Membrane Builder. We used the 652 
sequence GSSGGENQGG for the bound peptide in the holo simulations. This sequence is 653 
consistent with the observed density in the best-defined SusCD complex of the P1 structure 654 
(PDB ID 5QF8). For the apo simulations, the bound peptides were removed from the 655 
respective equilibrated structures and 20 ns of equilibration was carried out. Finally, a total of 656 
7 μs unbiased simulations were performed with no constraints on the system for the holo-657 
complexes (dimer and tetramer: 3 x 0.5 µs each and octamer: 1 x 0.5 µs) and apo-complexes 658 
(dimer and tetramer: 3 x 0.5 µs each and octamer: 1 x 0.5 µs).  659 
Data Availability. The datasets generated (coordinate files and structure factors) for 660 
BT2261-2264 have been deposited in the Protein Data Bank with accession codes 5FQ8, 661 
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5FQ7 and 5FQ6 for BT2261-2264 (space groups P1, P212121 and P21 respectively), 5FQ3 for 662 
BT2262 and 5FQ4 for BT2263. For BT1762-1763 the accession numbers are 5LX8 for 663 
BT1762 and 5T3R and 5T4Y for BT1762-63 (space groups P21212 and P212121 respectively). 664 
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 723 
EXTENDED DATA FIGURE LEGENDS 724 
Extended Data Fig. 1 | High abundance of SusCD complexes in B. theta OM. a, SDS-725 
PAGE gel of total outer membranes from E. coli (lanes 1,2,5,6) and B. theta (lanes 3,4,7,8). 726 
Each lane contains ~10 μg protein. Samples 5-8 were boiled (100). "P" denotes E. coli 727 
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trimeric porins OmpF/C, which migrate at their monomeric molecular weights (~35 kDa) 728 
only after boiling. Note the relative lack of small-molecule OM diffusion channels (~30-50 729 
kDa) in B. theta (lanes 7,8) and the low levels of large OM proteins including TBDTs (70-730 
120 kDa) in E. coli (lanes 5,6). Purified BT2261-2264 complex is shown in lanes 9 (non-731 
boiled) and 10 (boiled). b, Representative ion-exchange chromatogram from three separate 732 
experiments of B. theta total OM proteins separated on Resource-Q (6 ml, pH 7.5) after 733 
extraction in LDAO (Methods). Peaks A and B were further purified by gel filtration. c, SDS-734 
PAGE gel of purified SusCD complexes from peaks A and B. Numbered gel bands were 735 
excised and subjected to identification by mass spectrometry. d, SDS-PAGE gel of purified 736 
BT1762-63 complex before (*) and after boiling. The SusCD complexes are highly stable 737 
and remain intact in 2% SDS. 738 
 739 
Extended Data Fig. 2 | X-ray crystal structures of the small lipoproteins BT2261 and 740 
BT2262. a, Stereo cartoon of BT2261 within the BT2261-2264 complex with rainbow 741 
colouring (blue; N-terminus). BT2261 is O-glycosylated on Ser117, consistent with the 742 
presence of the Bacteroidetes glycosylation motif D-S/T-A/L/V/I/M/T 51. Ser117 is shown as 743 
a stick model. Fo-Fc density within 20 Å of Ser117 is shown as a green mesh contoured at 744 
3.0 σ. Three to four sugar moieties can be observed bound to Ser117. b, Stereo cartoon of 745 
soluble BT2262 with rainbow colouring. The protein consists of an N-terminal Ig-like 746 
domain and a C-terminal 8-stranded β-barrel. The functions of BT2261 and BT2262 are not 747 
clear, but both contain a small C-terminal 8-stranded β-barrel that displays structural 748 
similarity to lipid binding domains as judged by DALI 52. For BT2262, only one copy with a 749 
poorly ordered C-terminal domain is visible in the triclinic structure. Analogous to BT2263, 750 
the N-terminal segments of BT2261/62 that lead to the lipid anchors on the N-terminal 751 
cysteine residues are visible in the electron density; they are closely associated with SusC and 752 
do not appear to be flexible. Structures were determined using data obtained from a single 753 
crystal in each case. 754 
 755 
Extended Data Fig. 3 | The oligomeric nature of SusCD complexes is not a consequence 756 
of crystal packing. Cartoon side views of BT2261-2264 complexes rotated by 90° for space 757 
groups P1 (a), P212121 (b) and SeMet P21 (c). d, Cartoon side view of BT1762-1763 758 
(P212121). The protein backbones are coloured on the same scale by their B-factors (blue; 20 759 
Å2, red; 130 Å2). The grey bars indicate the hydrophobic phase of the OM. Structures were 760 
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determined using data obtained from a single crystal in each case. 761 
Extended Data Fig. 4 | BT2261-2264 and BT1762-1763 form oligomeric complexes. a, 762 
Mass spectrum of BT2261-2264 shows two prominent masses corresponding to an octamer 763 
and a ligand bound octamer in m/Z=12000-15000. b, Mass spectrum of BT1762-1763 764 
indicates that these two proteins form dimers and tetramers. The numbers in parentheses on 765 
the right are the theoretical masses. c, Analytical gel filtration chromatography of BT2261-64 766 
(blue) and BT1762-63 (green). For comparison, samples were run for soluble horse spleen 767 
ferritin (440 kDa; red) and for the membrane protein ammonium transporter Mep2 from 768 
Candida albicans (160 kDa; black). Buffer: 10 mM Hepes/100mM NaCl/0.12% DM pH 7.5. 769 
Column: Superdex-200 Increase 10/300 GL. d, Size-exclusion chromatography multi-angle 770 
light scattering (SEC-MALS) analysis of BT1762-63. Light scattering (LS) and differential 771 
refractive index (dRI) are plotted alongside the fitted total protein-detergent complex 772 
molecular weight (diamonds), and constituent protein (pluses) and detergent (crosses) 773 
molecular weights, across each peak. BT1762-63 eluted as two species of 499 kDa (protein 774 
component 319 kDa, corresponding to a SusCD dimer) and 269 kDa (protein component 214 775 
kDa). Chromatograms shown are from single experiments. 776 
Extended Data Fig. 5 | Unbiased electron density for the bound ligand in BT2261-64. 777 
Stereo views of simulated annealing omit maps using a starting temperature of 1000 K. a, 778 
2Fo-Fc maps contoured at 1.5 σ, carve=2. b, Fo-Fc map contoured at 3.0 σ, carve=2. 779 
Selected residues contacting ligand are shown (yellow; BT2264/SusC, magenta, 780 
BT2263/SusD). Density for at least six amino acid side chains is present (denoted with * in 781 
the 2Fo-Fc map). c, Interaction Table showing hydrogen bond distances between the putative 782 
peptide ligand backbone and residues in BT2263 and BT2264. 783 
 784 
Extended Data Fig. 6 | MD simulations for BT2261-64. a, Plots of BT2264 (SusC) 785 
Cα RMSD vs. simulation time for holo and apo complexes. b and c, Plots of BT2263 (SusD) 786 
Cα RMSD vs. simulation time for holo and apo simulations, relative to the starting 787 
conformation (b) and after SusD superposition (c). d,e Plots showing the number of hydrogen 788 
bonds between SusC and SusD vs. simulation time (d) and between holo SusCD and the 789 
modeled peptide (e). Simulations are numbered as follows: sim1-3, apo BT2263-64 (dimer); 790 
sim7-9, apo BT2261-64 (tetramer); sim13, apo (BT2261-64)x2 (octamer); sim4-6, holo 791 
BT2263-64; sim10-12, holo BT2261-64; sim14, holo (BT2261-64)x2. With the exception of 792 
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those of the octamer owing to its very large size, the simulations were repeated three times 793 
with different initial atomic velocities to allow sampling in order to obtain a measure of the 794 
possible spread in results. 795 
 796 
Extended Data Fig. 7 | Dynamics of the bound peptide during MD simulations. Side 797 
views (left panels) and top views showing the bound peptide in the BT2263-64 dimers (a), 798 
BT2261-64 tetramers (b) and the (BT2261-64)x2 octamer. For clarity, only one final 799 
conformation for BT2264 (SusC) is shown together with the starting conformation of the 800 
peptide (green) and the final peptide conformations after 500 ns of simulation (red). For 801 
orientation purposes the assigned N-termini of the peptides are coloured blue. 802 
 803 
Extended Data Fig. 8 | MD simulation root-mean-square-fluctuation (RMSF) analyses. 804 
(a) Cα
 
 RMSF values for SusC in holo and apo complexes with the conformational 805 
fluctuations of the hinge loop L7 highlighted separately. (b) Cα
 
 RMSF values for SusD in 806 
apo and holo simulations. Simulations are numbered as in Extended Data Fig. 6: sim1-3, apo 807 
BT2263-64 (dimer); sim7-9, apo BT2261-64 (tetramer); sim13, apo (BT2261-64)x2 808 
(octamer); sim4-6, holo BT2263-64; sim10-12, holo BT2261-64; sim14, holo (BT2261-809 
64)x2. 810 
Extended Data Fig. 9 | Structure of the BT2261-64 apo-octamer after 500 ns of MD 811 
simulation (sim13), demonstrating the independent bin opening of the two SusCD hubs. 812 
a, Views from the plane of the membrane rotated by 90º. b, View from the extracellular side. 813 
For clarity, the SusC and SusD subunits are shown in different colours (yellow and orange 814 
for SusC/BT2264, magenta and red for SusD/BT2263). BT2261 and BT2262 are shown in 815 
green and blue, respectively. c, Side view of the opened SusCD monomer highlighting the 816 
remaining interactions between SusC (yellow) and SusD (magenta) mediated by the hinge 817 
loop L7 and loop L8. 818 
 819 
Extended Data Fig. 10 | ITC analysis of levan binding for recombinant BT1762 SusD-820 
like wild-type and mutants. a, Titration curves from single experiments. Upper panels show 821 
raw injection heats of ligand (levan) into protein, lower panels show the integrated binding 822 
heats fit to a single set of sites binding model to determine Ka for all proteins except reduced 823 
wild-type (10 mM TCEP), W85A and C298A mutants that display no binding. Levan stock 824 
solution was between 0.5-2% (w/v) and protein ranged from 50-60 µM. b, Levan affinity of 825 
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recombinant BT1762 SusD-like wild type and mutant proteins determined by ITC.  Ka values 826 
shown are averages and standard deviations from at least two independent titrations. Residue 827 
numbering is that of the mature protein (first residue Cys1). 828 
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